Please use this identifier to cite or link to this item:
|Title:||Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times|
|Keywords:||Hoehn and Yahr stage|
|Citation:||Zhao, Y.J., Wee, H.L., Au, W.L., Seah, S.H., Luo, N., Li, S.C., Tan, L.C.S. (2011-03). Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times. Parkinsonism and Related Disorders 17 (3) : 194-197. ScholarBank@NUS Repository. https://doi.org/10.1016/j.parkreldis.2010.11.010|
|Abstract:||This study was carried out to evaluate the association between selegiline use and Parkinson's disease (PD) progression in a clinical sample by evaluating modified Hoehn and Yahr Stage (H and Y) stage transition times. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Cox regression analysis was used to examine the association between baseline variables and H and Y stage transition times. In multi-variate Cox regression analysis, patients who were of younger age, shorter PD duration, lower Unified Parkinson's Disease Rating Scale (UPDRS) motor scores, on selegiline treatment (≥3 years) and not on COMT inhibitors were associated with longer transition times from stage 2-2.5. Patients who were treated with selegiline (≥3 years) and not on COMT inhibitors experienced longer transition times from stage 2.5-3. In conclusion, selegiline use for 3 years or more in early PD was associated with a slower progression of PD as evaluated by H and Y transition times. © 2010 Elsevier Ltd.|
|Source Title:||Parkinsonism and Related Disorders|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 6, 2018
WEB OF SCIENCETM
checked on Nov 27, 2018
checked on Nov 10, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.